Atlas Trials

A Study of Relatlimab in Combination With Nivolumab in Participants With Advanced Liver Cancer Who Have Never Been Treated With Immuno-oncology Therapy After Prior Treatment With Tyrosine Kinase Inhibitors

Clinical trial NCT04567615 · COMPLETED

Trial details

NCT number
NCT04567615
Sponsor
Bristol-Myers Squibb
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Hepatocellular CarcinomaHepatomaLiver Cancer, AdultLiver Cell CarcinomaLiver Cell Carcinoma, Adult
Start date
2021-02-04
Primary completion
2023-08-31
Enrollment
266

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.